Heart health\ Ingredients - N°65 In the U.S.A., a cardiovascular product ratoire Lescuyer, said. Its validation tion representatives”. Lescuyer has its is being developed but, Marc Frémont would be a positive indicator not only own distinct distribution model: over the says, “ME-3 is mainly interesting for its for us but also for the entire profession Internet, by telephone, and by mail. With antioxidantapplications - liver health - .” And a reward for the efforts made Limicol, the consumers have a natural detoxi cation.” The same goes for Italy by the laboratory to develop a formula supplement without associated dis- and Australia. whose effectiveness is based on the comfort which, combined with dietary What about tomorrow? The positioning synergy of natural active ingredients advice, lowers their LDL cholesterol “metabolic syndrome” looks very promi- and has been demonstrated through levels. “Limicol embeds the DNA of the sing: a study conducted in collaboration its own clinical studies - 20% reduction laboratory,” Isabelle de Carmantrand with the University of Lille showed an in LDL-cholesterol levels. adds, namely “its commitment to inno- effect of ME-3 on the regulation of blood Could this food supplement be affected vation and sourcing quality ingredients glucose (after-meal limitation of the blood if EFSA published an opinion showing and a scienti cally proven ef ciency” . glucose peak), and especially on stea- that the consumption of monacolin K Besides Limicol, the laboratory also tohepatitis - 40% reduction in hepatic from red rice yeast incorporated in offers an Omega-3 formula based on triglyceride accumulation in db/db mice food supplements at a level of 10 mg/ an oil concentrate from cold-water sea (genetically obese and diabetic mice). The day poses a signifi cant risk to consumer wild fi sh (Peruvian anchovies) high in metabolic syndrome will be a major axis health? The answer is not so simple. omega-3 fatty acids in triglyceride form of development for VF Bioscience, even if On the one hand, because the yeast (60%) - EPA (30%) and DHA (20%) - the company does not fully abandon the is present at a concentration fi ve times bearing the labels EPAX® and Friend of segment of cardiovascular health as“the lower than the one of the claim. On the the Sea®. And for the circulatory system two are interconnected anyway,” Marc other hand, because its effectiveness is and artery protection, CardioMegaPro- Frémont concludes. given by the synergy of the active ingre- tect based on dry plant extracts (tur- dients. And fi nally, “because the labora- meric, garlic, hawthorn, black pepper), ◗Laboratoire Lescuyer tory approaches the prescribers - health vitamins E, B1, B2, B3, B6, taurine, argi- professionals - through its micronutri- nine, minerals... ■ On October 2nd, the European Com- 107 mission submitted to the World Trade Organization the draft text concerning the authorization of an Art. 14. claim on the reduction of disease risk targe- ting Limicol, a food supplement deve- loped by Laboratoire Lescuyer. Limicol, for which EFSA had issued a positive opinion related to this claim in 2013 - a fi rst in the sector of food supplements - is composed of artichoke leaf dry extract standardised in caffeoylquinic acids, monacolin K in red yeast rice, sugar-cane derived policonasols, procyanidolic oli- gomers (PCOs) from French maritime pine bark, dry garlic extract standardized in allicin, d-α-tocopheryl hydrogen suc- cinate (vitamin E), ribofl avin (vitamin B2) and inositol hexanicotinate (vitamin B3). The claim proposed was worded as follows: “The combination (of the listed ingredients) reduces blood LDL-cho- lesterol concentrations. High LDL-cho- lesterol levels area risk factor for coro- nary heart disease.” The claim comes with data protection for a period of fi ve years. “We have made many efforts to obtain EFSA’s appoal or this claim,” Isabelle de Carmantrand, CEO of Labo- News on Functional & Health Ingredients \ N°65 \ October - November - December 2018 \ ■